Reports Q4 revenue $14.8M, consensus $15.71M. “I joined Ocular because I see the opportunity to unlock significant value for patients and stockholders through the development of safe, effective and durable treatments for retinal diseases, starting with our lead candidate, AXPAXLI for wet AMD,” said Pravin Dugel, executive chairman of Ocular Therapeutix. “Bringing together our dedicated, world-class team of acknowledged strategic and clinical experts has enabled us to position Ocular as a leader in retinal care. Our goal is to bring AXPAXLI to the market as soon as possible. Our strengthened team provides us with an opportunity to enrich and accelerate the AXPAXLI clinical programs.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on OCUL:
- Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2023 Results
- Options Volatility and Implied Earnings Moves Today, March 11, 2024
- Ocular Therapeutix™ to Release Fourth Quarter and Full Year 2023 Results on March 11, 2024
- Ocular Therapeutix Inc (OCUL) Q4 Earnings Cheat Sheet
- Ocular Therapeutix options imply 8.8% move in share price post-earnings